| Name | Title | Contact Details |
|---|
Apria Healthcare is a Jacksonville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sport Tech is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Improving health is at the heart of Greenway Health`s work. We connect providers to the right information and insights, at the right place and time, so they can make patient-driven care a reality while navigating the ever-changing healthcare system. Greenway delivers exceptional service through a deep team of clinical, financial, and technology experts committed to innovations that keep people healthier and happier. We partner with over 8,000 organizations and 75,000 progressive providers across more than 40 specialties, which translates into more than 100 million lives that are touched by our solutions. All of Greenway Health`s solutions and services are designed to meet our company-wide goals of serving physicians, connecting the industry, and empowering better care. Whether as a customer, strategic partner, or staff member, you are invited to partner with us to create a smarter healthcare system.
Osseon Therapeutics is a Santa Rosa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."